Tyler Menichiello

Tyler Menichiello is a contributing editor to Bioprocess Online, Cell & Gene, and Clinical Leader. He interviews executives and subject matter experts across the biopharma industry to write about their successful approaches in biologics development from pre-IND planning all the way through trial design, manufacturing, and commercialization. He aims to investigate the industry’s most prevalent challenges and emerging best practices to provide both interesting and actionable content for industry leaders. Prior to writing for Life Science Connect, Tyler spent two years as a clinical research associate at the University of Pittsburgh Medical Center’s (UPMC) Hillman Cancer Center, where he worked on clinical trials involving hematological malignancies. He studied biology and journalism at Indiana University of Pennsylvania (IUP). You can email Tyler at tyler.menichiello@lifescienceconnect.com, or visit his LinkedIn profile.

ARTICLES BY TYLER MENICHIELLO

Treating Alzheimer's With NK Cell Therapy
5/8/2024

I met with NKGen Biotech's CEO, Dr. Paul Song, MD, to learn how a serendipitous discovery shifted the company's clinical focus from cancer to Alzheimer's disease.
Pioneering The First Cell Therapy For Solid Tumors
4/26/2024

I spoke to Iovance Biotherapeutics to learn about the company's preparation leading up to the approval of Amtagvi, the first FDA-approved tumor-infiltrating lymphocyte (TIL) therapy aimed at treating solid tumors.
Improving AAV Purity Upstream With PCL Manufacturing
3/21/2024

The downstream separation of AAV capsids affects end-product purity and has been identified as a key pain point of the industry. Ultragenyx’s Dennis Huang advises starting with higher-quality yields upstream.
Addressing The GMP Skills Shortage With Virtual Reality
2/14/2024

In the U.K., a professor at the University of Birmingham is using virtual reality (VR) to help address the growing biomanufacturing skills shortage — using virtual reality (VR).
Paving The Way For India’s First Domestic CAR-T Approval
1/22/2024

India recently saw the approval of its first domestic CAR-T cell therapy, NexCAR19. This not only marks a significant achievement for the country, but for the CGT industry as a whole. To learn more about this journey to approval, I met with ImmunoACT, the pioneer behind NexCAR19.
Treating Heart Disease With Gene Therapy
1/19/2024

Tenaya Therapeutics' TN-201 is a clinical-stage gene therapy aimed at treating the leading cause of death in the world — heart disease. Tenaya CEO, Faraz Ali, explains the company's journey in developing TN-201, as well as some lessons he's learned throughout his career, and what he's most excited to see in the field heading into 2024.
Preparing Your CAR-T Therapy For Phase 2 Trials
12/6/2023

AffyImmune CEO, Matt Britz, talks about what’s next for the company as it prepares its lead CAR-T candidate for Phase 2 trials — from clinical strategy to selecting a CDMO and the headache of tech transfers.
How Creative Licensing Can Improve Patient Access
11/16/2023

Members of Caring Cross and UC Berkeley's Innovative Genomics Institute and Office of IP And Industry Research Alliances discuss the important role technology transfer offices (TTOs) play in improving ATMP accessibility. TTOs can accomplish this by designing "strings-attached" research and licensing deals upstream in product development.
Important Ethical Questions Concerning CGTs
11/3/2023

This is a summary of Alliance For Regenerative Medicine's panel discussion, "The Importance Of Ethics In Gene And Cell Therapy," from this year's Meeting On The Mesa.
5 Takeaways From Meeting On The Mesa 2023
10/25/2023

This year's conference delivered outstanding networking, presentations, and panel discussions with industry leaders. Here are 5 of my favorite quotes from this year's participants.